SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Scarmeas N, Brandt J, Albert M et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch. Neurol. 2005; 62: 16011608.
  • 2
    Matsui T, Nakaaki S, Murata Y et al. Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life–Alzheimer's disease scale. Dement. Geriatr. Cogn. Disord. 2006; 21: 182191.
  • 3
    Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric symptoms and Quality of life in Alzheimer disease. Am. J. Geriatr. Psychiatry 2005; 13: 469474.
  • 4
    Albert SM, Jacobs DM, Sano M et al. Longitudinal study of Quality of life in people with advanced Alzheimer's disease. Am. J Geriatr. Psychiatry 2001; 9: 160168.
  • 5
    Burgener S, Twigg P. Relationships among caregiver factors and quality of life in care recipients with irreversible dementia. Alzheimer Dis. Assoc. Disord. 2002; 16: 88102.
  • 6
    Lyketsos CG, Gonzales-Salvador T, Chin JJ, Baker A, Black B, Rabins P. A follow-up study of change in quality of life among persons with dementia residing in a long-term care facility. Int. J. Geriatr. Psychiatry 2003; 18: 275281.
  • 7
    Selwood A, Thorgrimsen L, Orrell M. Quality of life in dementia: A one-year follow-up study. Int. J. Geriatr. Psychiatry 2005; 20: 232237.
  • 8
    Missotten P, Ylieff M, Di Notte D et al. Quality of life in dementia: A 2-year follow-up study. Int. J. Geriatr. Psychiatry 2007; 22: 12011207.
  • 9
    Rabins PV, Kasper JD, Kleinman L, Black BS, Patrick DL. Concepts and methods in the development of the ADRQL: An instrument for assessing health-related quality of life in persons with Alzheimer's disease. J. Ment. Health Aging 1999; 5: 3348.
  • 10
    Brod M, Stewart AL, Sands L, Walton P. Conceptualization and measurement of quality of life in dementia: The Dementia Quality of Life instrument (DQoL). Gerontologist 1999; 39: 2535.
  • 11
    Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer's disease: Patient and caregiver reports. J. Ment. Health Aging 1999; 5: 2132.
  • 12
    Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom. Med. 2002; 64: 510519.
  • 13
    Ready RE, Ott BR, Grace J. Patient versus informant perspectives of Quality of Life in Mild Cognitive Impairment and Alzheimer's disease. Int. J. Geriatr. Psychiatry 2004; 19: 256265.
  • 14
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA World Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939944.
  • 15
    Folstein MF, Folstein SE, McHugh PR. Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975; 12: 189198.
  • 16
    Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Caruso DA, Hombeam J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 23082314.
  • 17
    Hirono N, Mori E, Ikejiri Y et al. Japanese version of the Neuropsychiatric Inventory: A scoring system for neuropsychiatric disturbance in dementia patients. No To Shinkei 1997; 49: 266271 (in Japanese).
  • 18
    Hirono N, Yamadori A, Mori E, Yamashita H, Tokimasa A. Daily living activities of patients with Alzheimer's disease. Jpn. J. Neuropsychol. 1995; 11: 186195 (in Japanese).
  • 19
    Hirono N, Mori E, Yamashita H, Tokimasa A, Yamadori A. A novel scoring system of activities of daily living for patients with Alzheimer's disease: Hyogo Activities of Daily Living Scale (HADLS). Jpn. J. Neuropsychol. 1997; 13: 260269 (in Japanese).
  • 20
    Koss E, Patterson MB, Ownby R, Stuckey JC, Whitehouse PJ. Memory evaluation in Alzheimer's disease. Caregivers' appraisals and objective testing. Arch. Neurol. 1993; 50: 9297.
  • 21
    Maki N, Ikeda M, Hokoishi K et al. The validity of the MMSE and SMQ as screening tests for dementia in the elderly general population: A study of one rural community in Japan. Dement. Geriatr. Cogn. Disord. 2000; 11: 193196.
  • 22
    Vogel A, Mortensen EL, Hasselbalch SG, Andersen BB, Waldemar G. Patient versus informant reported quality of life in the earliest phases of Alzheimer's disease. Int. J. Geriatr. Psychiatry 2006; 21: 11321138.
  • 23
    Vasterling JJ, Seltzer B, Watrous WE. Longitudinal assessment of deficit unawareness in Alzheimer's disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 1997; 10: 197202.
  • 24
    Starkstein SE, Chemerinski E, Sabe L et al. Prospective longitudinal study of depression and anosognosia in Alzheimer's disease. Br. J. Psychiatry 1997; 171: 4752.
  • 25
    Sands LP, Ferreira P, Stewart AL, Brod M, Yaffe K. What explains differences between dementia patients' and their caregivers' ratings of patients' quality of life. Am. J. Geriatr. Psychiatry 2004; 12: 272280.
  • 26
    Stout JC, Wyman MF, Johnson SA, Peavy GM, Salmon DP. Frontal behavioral syndromes and functional status in probable Alzheimer disease. Am. J. Geriatr. Psychiatry 2003; 11: 683686.
  • 27
    Lam LCW, Tam CWC, Chiu HFK, Lui VWC. Depression and apathy affect functioning in community active subjects with questionable dementia and mild Alzheimer's disease. Int. J. Geriatr. Psychiatry 2007; 22: 431437.
  • 28
    Tekin S, Fairbanks LA, O'Connor S, Rosenberg S, Cummings JL. Activities of daily living in Alzheimer's disease: Neuropsychiatric, cognitive, and medical illness influences. Am. J. Geriatr. Psychiatry 2001; 9: 8186.
  • 29
    Lawton MP. Quality of Life in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1994; 8: 138150.
  • 30
    Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch. Neurol. 1999; 56: 13881393.
  • 31
    Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214219.
  • 32
    Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293303.
  • 33
    Rogers SL, Farlow MR, Doody RS, Mohs R, Freidhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136145.
  • 34
    Takeda A, Loveman E, Clegg A et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2006; 21: 1728.
  • 35
    Aalten P, Vugt ME, Jaspers N, Jolles J, Verhey FRJ. The course of neuropsychiatric symptoms in dementia. Part I: Finding from the two-year longitudinal Maasbed study. Int. J. Geriatr. Psychiatry 2005; 20: 523530.
  • 36
    Aalten P, Vugt ME, Jaspers N, Jolles J, Verhey FRJ. The course of neuropsychiatric symptoms in dementia. Part II: Relationships among behavioural sub-syndromes and the influence of clinical variables. Int. J. Geriatr. Psychiatry 2005; 20: 531536.